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Summary
Objective: Abnormal maturation and ossiﬁcation of the endplate chondrocytes play a central role in the pathogenesis of degenerative disor-
ders of the cervical spine. It is widely held that insulin like growth factor-1 (IGF-1) stimulates chondrocyte proliferation and inhibits chondrocyte
terminal differentiation both in vitro and in vivo. However, the mechanism underlying such regulation is not fully understood. The present study
aimed to determine the role of IGF-1 on the mRNA expression of collagen type II, alpha 1 (Col2a1) and matrix metallopeptidase 13 (MMP-13)
in rat endplate chondrocytes. The possible pathways that transduce IGF-1 effects such as phosphatidylinositol-3 (PI-3)-kinase (PI3K) and mi-
togen activated protein kinase (MAPK) were also investigated in these cells.
Methods: Cultured endplate chondrocytes harvested from rat cervical spines were treated with IGF-1 (100 ng/ml), and the changes in Col2a1
and MMP-13 mRNA were monitored with real-time polymerase chain reaction (PCR). MMP-13 activity was also assayed. Activation of sig-
naling proteins was evaluated by western blot analysis. Cells were also treated with pharmacological agents that block PI3K and MAPK sig-
naling pathways.
Results: IGF-1 increased Col2a1 mRNA expression in rat endplate chondrocytes in a time- and dose-dependent manner. IGF-1 treatment
resulted in a fourfold increase of Col2a1 mRNA with the effect maximizing at 24 h. In contrast, IGF-1 treatment for 24 h caused a roughly
50% reduction in MMP-13 mRNA. Similar effects were seen on the protein levels of type II collagen (col2) and MMP-13. Consistent with these
results, IGF-1 also repressed MMP-13 activity. IGF-1 activated both the PI3K and the extracellular signal-regulated kinase (ERK) pathways as
evidenced by phosphorylation of either Akt or ERK1/2 (respectively). The PI3K inhibitor Wartmannin signiﬁcantly inhibited the IGF-1 effect on
Col2a1 mRNA expression but did not affect IGF-1-induced repression of MMP-13 expression. In contrast, the ERK/MAPK inhibitor PD98059
signiﬁcantly inhibited the effect of IGF-1 on MMP-13 mRNA repression and enhanced IGF-1-induced Col2a1 mRNA expression.
Conclusions: In rat endplate chondrocytes the PI3K pathway mainly transduces IGF-1 effect on col2 expression while the ERK pathway
mediates IGF-1 effect on MMP-13 expression.
ª 2008 Osteoarthritis Research Society International. Published by Elsevier Ltd. All rights reserved.
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Neck pain is one of the most common chronic conditions. It
severely affects quality of life and eventually leads to
disability in adults. Degeneration of intervertebral discs
(IVDs) in the cervical spine plays a central role in the
pathogenesis of discogenic pain, disc herniation, spinal
instability and stenosis, and facet joint osteoarthritis1,2. It is
reported that disc degeneration affects 95%of the population
over age50.Abnormalmaturationandossiﬁcation of cartilag-
inous endplates adjacent to IVD hinder the transport of nutri-
ents and ions between disc cells and surrounding tissues,aBoth authors contributed equally to this work.
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100eventually altering the normal function of disc cells. Patho-
logic changes include decreased synthesis of extracellular
matrix (ECM) proteins and local accumulation of destructive
enzymes3,4. Therapeutics for degenerative diseases of the
cervical spine may be developed by increasing synthesis of
ECMmolecules such as type II collagen (col2) and by inhibit-
ing destructive enzymes such asMMPs. Amongmembers of
the MMP superfamily, MMP-13 has been shown to degrade
col2 in diseased IVD5e13.
IGF-1 is a growth factor capable of inhibiting apoptosis of
endplate chondrocytes and increasing local synthesis of
proteglycans14e17. These properties make IGF-1 a promis-
ing therapeutic candidate for spinal degenerative
diseases18. However, the mechanism through which IGF-
1 regulates col2 and MMP-13 expression in endplate chon-
drocytes needs to be further elucidated before any possible
clinical use may be realized.
IGF-1 exerts its biological effect by binding to the trans-
membrane type 1 IGF receptor and activating insulin recep-
tor substrate-1. Insulin receptor substrate acts as a docking
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pathways have been reported to mediate IGF-1 effects,
namely, phosphatidylinositol-3 (PI-3)-kinase (PI3K)eAkt
and mitogen activated protein kinase (MAPK)/extracellular
signal-regulated kinase (ERK)1/2 pathways19e21. The
purpose of our present study is to identify the speciﬁc path-
ways mediating different IGF effects on col2 and MMP-13
expression in rat endplate chondrocytes.
Endplate cartilage lies between the trabecular bone of
vertebral bodies and IVDs. It can be roughly divided into
two layers, a calciﬁed layer conjoining the trabecular
bone of the vertebral body and a non-calciﬁed layer facing
the IVD. Abnormal maturation and ossiﬁcation of the chon-
drocytes in the non-calciﬁed layer impede the nutrient sup-
ply to IVD, thereby inducing degenerative changes in the
spine. Investigation of the biological behavior of endplate
chondrocytes may provide novel insight into the pathogen-
esis of degenerative spinal diseases. In the present study,
we decided to harvest endplate chondrocytes from 4-
week-old rats. Based on our previous experience this is
the optimum time point for harvest; in rats older than 4
weeks the endplates become signiﬁcantly thinner, while
in rats younger than 4 weeks the number of chondrocytes
that can be harvested is much lower, probably due to the
relatively small size of vertebral bodies and endplates in
younger rats.Material and methodsCHONDROCYTE ISOLATION AND CULTURE14Primary chondrocytes were isolated from the endplate cartilage of the cervi-
cal spine of 4-week-old SpragueeDawley rats. The cartilage endplate of the
C1eC7was carefully removed from the vertebrae andminced into small pieces
(<0.3 mm3). Samples were sequentially digested with 0.2% trypsin (Sigma, St.
Louis, MO) at 37C for 20 min followed by 0.02% collagenase (Sigma) at 37C
for 24 h. The digested tissue was ﬁltered through a 100-mm cell strainer (BD
Biosciences, Bedford, MA). Cells were washed with phosphate-buffered saline
(PBS), then plated at a density of 2 104 cells/cm2 in tissue culture ﬂasks and
cultured at 37C and 5% CO2. Primary chondrocytes were maintained in
a high-density monolayer culture for 1 week in Dulbecco’s Modiﬁed Eagle
Medium (DMEM, Gibco, NY) supplemented with 10% fetal bovine serum
(FBS, HyClone, Logan, UT) and 1% penicillin/streptomycin (Invitrogen, Carls-
bad, CA) before subsequent experiments. Wartmannin (an inhibitor of PI3K,
upstream of Akt) and PD98059 (an inhibitor of mitogen-activated protein kinase
(MEK), upstream of ERK) were used in some experiments to block speciﬁc
pathways.CELL VIABILITYAfter 1 week in culture in DMEM containing 10% FBS, primary endplate
chondrocytes were trypsinized and subcultured in 96-well plate (5000 cells
per well) in DMEM containing 10% FBS for 24 h. To examine the cell viability,
the chondrocytes of the second passage were treated with excessive
amount of either Wartmannin (50 nM) or PD98059 (25 mM) for 24 h. Cell-
titer-Blue reagent (Promega, WI) was directly added to the plate (20-ml
reagent to each well containing 100-ml medium) and incubated at 37C for
3 h. The ﬂuorescence signaling was measured by a spectroﬂuorometer (Mo-
lecular Device, Sunnyvale, CA).RNA EXTRACTION AND REAL-TIME PCRRNAwas harvested using the RNAeasy kit (Qiagen, Valencia, CA) perman-
ufacturer’s protocol. Total RNA (1 mg)was reverse-transcribed using theAdvan-
tage RT-for-PCR kit (Qiagen) following the manufacturer’s protocol. Freshly
reverse-transcribed cDNA was used for real-time PCR, and SYBR Green
(Bio-Bad, Hercules, CA) was used to monitor DNA synthesis. The following
rat primers were used: Col2a1: forward: 50 TCCTAAGGGTGCCAATGGTGA
30, reverse: 50 AGGACCAACTTTGCCTTGAGGAC 30; MMP-13: forward: 50
CCCTGGAGCCCTGATGTTT 30, reverse: 50 CTCTGGTGTTTTGGGGTGCT
30; b-actin: forward: 50 GGAGATTACTGCCCTGGCTCCTA 30, reverse: 50
GACTCATCGTACTCCTGCTTGCTG30. PCRwas carried out using the Rotor-
Gene real-time DNA ampliﬁcation system (Corbett Research, Sydney,Australia) using the following cycling protocol: a 95C denaturation step for
5 min followed by 40 cycles of 95C denaturation (20 s), 62C annealing
(20 s), and 72C extension (20 s). Detection of the ﬂuorescent product was car-
ried out at the end of the 72C extension period. Gene expression was normal-
ized to b-actin. PCR products were subjected tomelting curve analysis, and the
data were analyzed and quantiﬁed using RotorGene analysis software. Actino-
mycin D (a transcription inhibitor) or cycloheximide (a protein synthesis inhibitor)
was used in some experiments.WESTERN BLOT ANALYSISAfter 1 week in culture in DMEM containing 10% FBS, primary endplate
chondrocytes were trypsinized and then subcultured in DMEM containing
10% FBS for 24 h. These cells were marked as second passage chondro-
cytes and were lysed in Golden lysis buffer supplemented with protease
inhibitor (Boehringer Manheim), 1-mM sodium orthovanadate, 1-mM ethyle-
neglycol-bis-(b-aminoethyl ether), 1-mM sodium ﬂuoride, and 1-mM micro-
cysteine (Sigma). Protein concentrations were quantiﬁed using the
Coomassie Plus Protein Assay Kit (Bio-Rad). Thirty micrograms of protein
extract were separated by sodium dodecyl sulfate polyacrylamide gel elec-
trophoresis (SDS-PAGE) and then transferred to a polyvinylidene ﬂuoride
(PVDF) membrane (NEN Life Science Products Inc., Boston, MA). The blots
were probed overnight at 4C with either rabbit anti-rat phospho Akt antibody
(Cell Signaling Inc.) or phospho ERK1/2 antibody (Upstate Inc.). After wash-
ing, the membranes were incubated for 1 h at 20C with goat anti-rabbit-IgG
(Oncogen, Boston, MA). Immune complexes were detected using Odyssey
infrared imaging system (LI-COR Bioscience Inc.). For re-probing, the immu-
nocomplex was removed by an incubation of the membrane in the Re-blot
Plus Strong Solution (Chemicon, Temecula, CA) for 10 min. Non-speciﬁc sig-
nals were blocked by incubation of the membrane in 5% milk for 60 min. After
the removal of excess milk, the membrane was incubated with primary anti-
mouse b-actin antibody (1:5000, Sigma, IL). Subsequent steps were carried
out following the same procedure as in the ﬁrst blotting.MMP-13 ACTIVITY ASSAYThe second passage chondrocytes were lysed in M-PER buffer (Pierce,
Rockford, IL). Once homogenized, extracts were centrifuged at 14,000 g
and the supernatants were collected and stored at 80C until use. Total
protein content was determined by the bicinchoninic acid (BCA) method
(Pierce, Rockford, IL). MMP-13 enzymatic activity was analyzed with the
ﬂuorescent substrate Dnp-PChaGCHAK9Nma as per the manufacturer’s in-
structions (BIOMOL, Plymouth Meeting, PA) and assayed at 37C using
a substrate concentration of 10 mM in buffer containing 500-mM 4-(2-hydroxy-
ethyl)-1-piperazineethanesulfonic acid (HEPES), 100-mM CaCl2, and 0.5%
Brij-35 (pH 7.0). The method to determine the amount of MMP-13 speciﬁc ac-
tivity was adding the MMP-13 inhibitor to the enzyme reaction (Calbiochem,
NJ). Fluorometric measurements were made in a Molecular Device spectroﬂu-
orometer (Gemini EM, CA). Fluorescence was detected using excitation at
340 nm, and emission measured at 440 nm.STATISTICAL ANALYSISA Student’s t test was done for all statistical analyses using SPSS 10.0
software (SPSS, Chicago, IL); signiﬁcance was deﬁned by P values less
than 0.05.ResultsIGF-1 UPREGULATES col2 EXPRESSIONIGF-1 enhances Col2a1 mRNA expression in rat end-
plate chondrocytes in a dose- and time-dependent man-
ner. In a subconﬂuent monolayer culture, the stimulatory
effect of IGF-1 on Col2a1 mRNA expression was seen at
levels as low as 20 ng/ml. When used at a dose of
100 ng/ml IGF-1 induced a fourfold increase in Col2a1
mRNA expression. The time-course study demonstrated
that IGF-1 effected Col2a1 expression as early as 8 h
and peaked at 24 h. To conﬁrm the effect of IGF-1 on
the protein expression of col2, we treated the endplate
chondrocytes with IGF-1 for 24 h and performed a western
blot analysis. The results showed that IGF-1 increased the
protein level of col2 when used at either 50 ng/ml or
100 ng/ml (Fig. 1).
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Fig. 1. Monolayer culture of the endplate chondrocytes isolated from cervical spine of rats was synchronized in serum-free medium for 12 h
and treated with IGF-1 for additional 12 h. After RNA extraction and reverse transcription, Col2a1 mRNA expression was assessed by real
time polymerase chain reaction (RT-PCR). The bars represent the meanSE of three independent experiments. *P< 0.05, **P< 0.01 vs
control. (A) IGF-1 stimulated Col2a1 mRNA expression in a dose-dependent manner. (B) IGF-1 stimulated Col2a1 mRNA expression in
a time-dependent manner. (C) Conﬂuent endplate chondrocytes in monolayer culture were switched to serum-free media, cultured 12 h
and then treated with IGF-1 (0, 50 and 100 ng/ml) for 24 h. Protein samples were collected and western blot was performed with an antibody
against col2. b-actin was used as a loading control.
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DE NOVO GENE TRANSCRIPTIONTo identify whether the IGF-1 induced increase of Col2a1
mRNA was caused by increased gene transcription and/or
decreased mRNA degradation, we used the transcription
blocker actinomycin D. Actinomycin D alone did not affect
Col2a1 mRNA expression, but it completely abolished the
IGF-1 effect on Col2a1. The protein synthesis inhibitor,
cycloheximide, had similar effect. These results suggest
that the IGF-1 induced Col2a1 mRNA expression resulted
from de novo gene transcription (Fig. 2).IGF-1 DOWNREGULATES MMP-13 EXPRESSIONIGF-1 inhibits MMP-13 expression in rat endplate chon-
drocytes in a dose- and time-dependent manner. The inhib-
itory effect of IGF-1 was seen at a dose of 50 ng/ml, and thisBA
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Fig. 2. Subconﬂuent endplate chondrocytes in monolayer culture were sy
(100 ng/ml) alone or in combination either with actinomycin D (A) or cyclo
mRNA expression was assessed by real time RT-PCR. The bars represe
control; #P< 0.05 vs IGF-1. A-D, actineffect became more signiﬁcant when the dose was
increased to 100 ng/ml. A time-course study showed that
the inhibitory effect of IGF-1 on MMP-13 peaked at 24 h.
Western blot analysis demonstrated that IGF-1, when
used at either 50 ng/ml or 100 ng/ml, decreased the protein
level of MMP-13 (Fig. 3).IGF-1 INHIBITS MMP-13 ACTIVITYA kinetic assay of MMP-13 enzymatic activity was done,
and measurements of ﬂuorescence intensity were taken at
different time points from 5 min to 60 min. Our results
clearly showed that IGF-1, in addition to its effect on
MMP-13 expression, also inhibits enzymatic activity of
MMP-13. These results were further conﬁrmed in the
presence of an MMP-13 inhibitor, which showed that IGF-
1 has a speciﬁc effect on MMP-13 activity (Fig. 4).*
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Fig. 3. Subconﬂuent endplate chondrocytes in monolayer culture were synchronized in serum-free medium for 12 h and stimulated by IGF-1
for additional 12 h. RNA was extracted and MMP-13 mRNA expression was assessed by real time RT-PCR. The bars represent the meanSE
of three independent experiments. *P< 0.05, **P< 0.01 vs control. (A) IGF-1 inhibited MMP-13 mRNA expression in a dose-dependent manner.
(B) IGF-1 inhibited MMP-13 mRNA expression in a time-dependent manner. (C) Conﬂuent endplate chondrocytes in monolayer culture were
switched to serum-free media for 12 h and then treated with IGF-1 (0, 50 and 100 ng/ml) for 24 h. Protein samples were collected and western
blot was performed with an antibody against MMP-13. b-actin was used as a loading control.
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Fig. 4. (A) Kinetic assay of the MMP activity showed that IGF-1 re-
pressed MMP activity. (B) Normalized results with MMP-13 speciﬁc
inhibitor demonstrated that IGF-1 speciﬁcally inhibits MMP-13 en-
zymatic activity. *P< 0.05.
103Osteoarthritis and Cartilage Vol. 17, No. 1IGF-1 ACTIVATES THE ERK MAPK AND Akt PATHWAYSTo identify the signaling pathway through which IGF-1 ex-
hibits its effects in rat endplate chondrocytes, we performed
a western blot using an antibody against phospho ERK. Our
results showed that IGF-1, when used at either 50 ng/ml or
100 ng/ml, induced ERK phosphorylation. PD98059, an in-
hibitor of MEK, a kinase upstream of ERK, almost com-
pletely blocked IGF-1-induced ERK1/2 phosphorylation
[Fig. 5(A) and (B)]. In addition, IGF-1 treatment (50 ng/ml
and 100 ng/ml) activated the Akt signaling pathway as evi-
denced by the phosphorylation of Akt. Wartmannin, an in-
hibitor of PI3K, a kinase up stream of Akt, partially
blocked IGF-1-induced Akt phosphorylation [Fig. 5(C) and
(D)]. Study of cell viability showed that neither PD98059
nor Wartmannin have obvious cytotoxicity [Fig. 5(E)].IGF-1 REGULATES Col2a1 AND MMP-13 EXPRESSION VIA
DIFFERENT PATHWAYSIn endplate chondrocytes, inhibition of Akt with Wartman-
nin blocked IGF-1-induced Col2a1 expression, which was
statistically signiﬁcant (P< 0.01). However, inhibition of
ERK with PD98059 increased the IGF-1-induced Col2a1
expression. PD98059 completely abolished the inhibitory
effect of IGF-1 on MMP-13 mRNA expression, while IGF-
1-induced MMP-13 expression was not affected by the inhi-
bition of Akt by Wartmannin (Fig. 6). These data suggest
that IGF-1 regulates col2 expression through the PI3KeAkt
pathway and MMP-13 expression through the ERK MAPK
pathway.Discussion
IGF-1 is a key anabolic factor involved in the growth and
differentiation of normal cartilage tissue. We have reported
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Fig. 5. Subconﬂuent endplate chondrocytes in monolayer cultures were switched to serum-free media for 12 h and then treated with IGF-1 (0,
50 and 100 ng/ml) for 15 min. Cell lysates were prepared and western blot was done with an antibody against either phospho ERK1/2 (A) or
Akt (C). Chondrocytes were pretreated with either MEK inhibitor PD98059 (25 mM, B) or PI3K inhibitor Wartmannin (50 nM, D) for 60 min,
followed by stimulation with IGF-1 (50 ng/ml) for 15 min. Cell lysates were prepared and western blot was done with an antibody against either
phospho ERK1/2 or Akt. (E) The cell viability assay using the Celltiter-Blue reagent expressed as ﬂuorescence intensity.
104 M. Zhang et al.: IGF-1 signaling in endplate chondrocytesthat IGF-1 can prevent Fas antibody-induced apoptosis and
increase proteoglycan synthesis in endplate chondro-
cytes14. Our present study demonstrates for the ﬁrst time
that IGF-1 upregulates col2 expression at both the mRNA
and protein level in rat endplate chondrocytes isolated
from the cervical spine and that the IGF-1 induced Col2a1
gene expression requires de novo mRNA transcription
and de novo protein synthesis.
MMP-13 is a collagenolytic enzyme expressed at high
levels in developing bone and cartilage, able to cleave
ECM proteins including col2. Our results show that IGF-1
treatment downregulates MMP-13 expression and re-
presses MMP-1 enzymatic activity. IGF-1 enhanced col2 ex-
pression may result from a direct signaling effect as well as
indirectly via suppression of MMP-13 expression. MMP-13
is also considered to be amarker of terminal chondrocyte dif-
ferentiation22. In combination with our previous studies, we
conclude that IGF-1 helps maintain endplate cartilage in
a prehypertrophic stage and prevents its abnormal matura-
tion and ossiciﬁcation by increasing the synthesis of ECM
proteins. IGF-1 can also prevent spinal degenerative
changes by inhibiting the local production of MMP-13.
To further understand the mechanisms underlying IGF-1
effects on chondrocytes we investigated possible signal
transducing pathways. PI3KeAkt and ERK MAPK pathways
were selected as these two pathways have been widely ac-
cepted as major pathways mediating IGF-1 effects in other
cell types. By western blotting with phospho-antibodies and
using speciﬁc inhibitors, we were able to distinguish the ex-
act pathways transducing different IGF-1 effects. Although
both pathways were activated by IGF-1, activation ofPI3KeAkt, but not ERK, was required for Col2a1 expression
in rat endplate chondrocytes. Chemical inhibition of PI3K,
and therefore deactivation of Akt, abolishes the IGF-1 in-
duced col2 upregulation. Interestingly, the MEK inhibitor
PD98059, which inhibits ERK activation, works synergisti-
cally with IGF-1 to increase col2 expression, indicating that
the ERKMAPK pathway itself may suppress col2 expression
in chondrocytes.
A previous study has demonstrated that IGF-1 inhibits
MMP-13 expression in articular chondrocytes23. We
obtained a similar ﬁnding in rat endplate chondrocytes.
Furthermore, we observed that chemical inhibition of ERK
resulted in a complete reversal of IGF-1-mediated MMP-
13 suppression, suggesting that the ERK pathway is
involved in the suppression of MMP-13 mRNA expression
by IGF-1. It has been reported that interleukin-1 (IL-1) stim-
ulates MMP-13 expression in an ERK-dependent manner in
human articular chondrocytes24. Although IGF-1 and IL-1
had opposite effects on MMP-13 expression, they exert
their effects through the same signaling pathway, possibly
by activating different downstream transcription factors.
In addition to its role in the mediation of Col2a1 and
MMP-13 expression, IGF-1 is capable of promoting
chondrocyte survival25,26. In various cell types other than
chondrocytes, IGF-1 survival signaling involves the activa-
tion of the PI3K/Akt pathway, although additional pathways
appear to be capable of promoting chondrocyte survival as
well27,28. IGF-1 prevents cell apoptosis through activation of
the ERK/MAPK signaling pathway in chondrocyte cul-
tures29. Under the conditions of the present study, no signif-
icant changes in cell death were observed with inhibition of
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Fig. 6. Subonﬂuent chondrocytes were cultured in serum-free
medium for 12 h and stimulated by IGF-1 (100 ng/ml) alone or in
combination either with PD98059 (25 mM) or Wartmannin (50 nM).
After 24-h incubation, RNA was extracted and Col2a1 mRNA
expression (A) and MMP-13 mRNA expression (B) were assessed
by real time RT-PCR. The columns represent the meanSE of
three independent experiments. *P< 0.05 vs control. #P< 0.05
vs IGF-1 treatment. Bar 1: control, 2: IGF-1 alone, 3: IGF-1 plus
PD98059, 4: IGF-1 plus Wartmannin.
105Osteoarthritis and Cartilage Vol. 17, No. 1either the PI3KeAkt pathway or the ERK/MAPK signaling
pathway in endplate chondrocytes. We postulate that
some kind of compensative mechanism exists for cell
survival.
In conclusion, the results demonstrated that IGF-1 stimu-
lation of Col2a1 expression in rat endplate chondrocytes
required the activation of the PI3KeAkt kinase signaling
pathway but not the ERK pathway, whereas IGF-1 stimula-
tion of the ERK/MAPK signaling pathway is responsible for
inhibition of MMP-13 expression. Our ﬁndings provide new
insight into the molecular mechanism underlying the patho-
genesis of degenerative spinal diseases and may aid in the
development of future therapeutic interventions.Conﬂict of interest
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